The U.S. Supreme Court is going to take up a case that could have a major impact on the patentability of genes used in diagnostics. The Supreme Court will review a case concerning Myriad Genetics ($MYGN), which won a decision from the U.S. Court of Appeals for the Federal Circuit in August. Myriad and other companies seeking novel genetic findings say that patents are important to protecting their investments in innovation. We'll see what the justices think about it. Article